The trial runs in the UK as well, so it may be more feasible to you.
Note, this is a phase 1 trial. Often oncologists get very upset when people say “promising results” for phase 1 where you are just trying to figure out how much of the drug you can give. That in the lab Lorlatinib has worked much better than Crizotinib.